Table 1.
Clinical and disease-related characteristics of the PLHIV population.
| Mode of Transmission | ||
|---|---|---|
| Heterosexual intercourse | 271 | 95.1% |
| Mother to Child | 12 | 4.2% |
| Unknown | 2 | 0.7% |
| Partner’s HIV status | ||
| HIV-positive partners | 126 | 44.2% |
| HIV-negative partners | 61 | 21.4 |
| Mother is-positive or Both parents are-positive | 8 | 1.4% |
| Missing information (Unknown status) | 90 | 31.6% |
| Family size | ||
| 3-Member Families | 60 | 21.1% |
| 4-Member Families | 79 | 27.7% |
| >5-Member Families | 35 | 12.4% |
| Not Recorded | 43 | 15.1% |
| ≤2 * | 68 | 23.9% |
| Entry Point to healthcare system | ||
| VCTC | 168 | 58.94% |
| OPD | 32 | 11.22% |
| Pvt Practitioner | 78 | 27.36 |
| PPTCT | 3 | 1.5% |
| NGO | 3 | 1.5% |
| IP | 1 | 0.35% |
| Previous antiretroviral (ARV) usage prior to enrollment in the NACO Program | ||
| Yes | 105 | 36.8% |
| No | 137 | 48.1% |
| Unspecified or Missing information | 43 | 15.1% |
| World Health Organization (WHO) Clinical Stage at the initiation of ART | N | % |
| Stage-I | 194 | 68.1% |
| Stage-II | 18 | 6.3% |
| Stage-III | 22 | 7.7% |
| Stage-IV | 51 | 17.9% |
| History of TB | 76 | 26.7% |
|
61 15 |
21.4% |
| TB Treatment Status | ||
| Ongoing | ||
| Cure | ||
| Completed | ||
| Baseline CD4 at the time of study enrollment (in cells/mm3) | ||
| >500 | 145 | 50.9% |
| 200–499 | 115 | 40.4% |
| <200 | 25 | 8.8% |
| >500 | 145 | 50.9% |
| End of the study CD4 (current status) | ||
| >500 | 139 | 48.8% |
| 200–499 | 102 | 35.8% |
| <200 | 18 | 6.3% |
| Missing | 26 | 9.1% |
| Baseline HIV Viral Load (HIV RNA copies) at the time of study enrollment | ||
| Target Not Detected | 172 | 60.4% |
| Below 20 copies/mL | 36 | 12.6% |
| >20–1,000,000 copies/mL | 66 | 23.2% |
| Above 1,000,000 copies/mL | 11 | 3.9% |
| End of the study Viral Load (HIV RNA copies) | ||
| Target Not Detected | 156 | 54.7% |
| Below 20 copies/mL | 31 | 10.9% |
| >20–1,000,000 copies/mL | 67 | 23.5% |
| Above 1,000,000 copies/mL | 4 | 1.4% |
| Initiated regimen after the diagnosis of HIV infection | ||
| Protease inhibitor-Based Regimen | 5 | 1.75% |
| Nucleoside RT Inhibitors-Based Regimen | 203 | 71.22% |
| Non-Nucleoside RT Inhibitors-Based Regimen | 77 | 27.01% |
| Integrase Inhibitors-Based Regimen | 0 | 0% |
| Regimen at the time of study enrollment (Baseline) | ||
| Protease inhibitor-Based Regimen | 62 | 21.75% |
| Nucleoside RT Inhibitors-Based Regimen | 147 | 51.57% |
| Non-Nucleoside RT Inhibitors-Based Regimen | 00.00 | 00.00 |
| Integrase Inhibitors-Based Regimen | 76 | 26.66% |
|
223 | 78.24% |
|
62 | 21.75% |
Voluntary Counseling and Testing for HIV (VCTC), Outpatient Department (OPD), Prevention of Parent-to-Child Transmission of HIV (PPTCT), Nongovernmental Organization (NGO), Inpatient (IP), Tuberculosis (TB), Pulmonary Tuberculosis (TB), Extrapulmonary Tuberculosis (EPTB); * Unmarried, Divorced.